Lin Bioscience, Inc. · TPEX:6696
Lin Bioscience — Investor Presentation (2022)
23 slides from Lin Bioscience's investor presentation, Apr 14, 2022
Slide 1: Blindness & Cancer
Blindness & Cancer 2022
Slide 2: Novel Treatment for Unmet Medical Need
Novel Treatment for Unmet Medical Need Lin Bioscience is a clinical stage drug development company focused on sourcing/advancing novel therapeutic candidates in areas with significant unmet need. The Company’s pipeline consists of RBP4 IP portfolio, CDC7 platform technology and 4 distinct small mole
Slide 3: Pipeline
Pre- Discovery Phase 1 Phase 2 Phase 3 MARKET Clinical Pipeline Sponsored by NIH BPN Developed by Belite Bio™ Dry AMD Stargardt Disease Obtained FDA RPD, FDA ODD, & EMA ODD (juvenile macular degeneration) RBP4 IP Portfolio Non Alcoholic Fatty Liver Disease (NASH) / Type 2 Diabetes Sponsored by Taiwa
Slide 4: Management Team
Management Team Tom Lin, MMED, PhD, MBA • PhD in Medicine - University of Sydney; Specialization: Neurology & Immunology o Treatment Strategies for Autoimmune Neuropathies (CEO) • Specialist Certificate in Clinical Neuroscience - University of Melbourne; Specialization: Neurology o Neurological Diso
Slide 5: Management Team
Management Team Irene Wang, PhD, MBA Hao-Yuan Chuang, CFA, MBA, FRM Yvonne Chen (CSO) (CFO) (COO) • PhD in Biochemical Sciences, National Taiwan • MBA from Columbia University • Certified pharmacist & master in Science University, Trained at Scripps Research (TSRI), (Medicinal Chemistry) from Nation
Slide 6: Ophthalmology Clinical Advisory Board
Ophthalmology Clinical Advisory Board Global leading experts on dry age-related macular degeneration and Stargardt disease • Dr. Frank Holz: Chairman • Dr. Michel Michaelides: Consultant Ophthalmologist at • Dr. Quan Nguyen: Professor of of Ophthalmology, Moorfields Eye Hospital and Professor of Oph
Slide 7: LBS-008 for Dry AMD & Stargardt Disease
LBS-008 FOR DRY AMD & STARGARDT DISEASE 7
Slide 8: Zero Approved Treatments: Hope to Incurable Blindness
HOPE TO INCURABLE BLINDESS For dry AMD & Stargardt Disease Discovery Preclinical Phase 1 Phase 2 KEY OPPORTUNITY Dry AMD MARKET STGD1 MARKET ✓ Phase 3 MARKET Zero Approved 11M 1 in 10,000 Treatments AMD patients in the US (90% are dry AMD) Stargardt Disease Juvenile onset macular degeneration RPD OD
Slide 9: LBS-008 Mechanism of Action
LBS-008 Induced Enzymes Down-Regulation LBS-008 Mechanism of Action Visual Pigment Retinoids Visual Chromophore Rhodopsin 11c-Ral at-Ral STARGARDT PHOTORECEPTORS A2E Gene mutation (PR) causes loss of ABCA4 ABCA4 transporter function Mutation of ABCA4 causes at-RDH accumulation of vitamin A 11c-RDH a
Slide 10: Pathogenesis of STGD1
Pathogenesis of STGD1 Case Study in the ProgStar study: • Fundus autofluorescence (FAF) photography from a STGD1 patient at ‘baseline’ and 22 months later showed that the autofluorescence (i.e, bisretinoid-laden lipofuscin) precedes lesion growth. The pattern (type of FAF) and nature of the lesions
Slide 11: Pathogenesis of STGD1 & Dry AMD
STGD1 and dry AMD share a similar pathophysiology which is characterized by the aberrant and excessive accumulation of cytotoxic bisretinoid fluorophores, subsequent retinal atrophy, and vision loss Pathogenesis of STGD1 & Dry AMD Reference: Lindner et al. Differential Disease Progression in Atrophi
Slide 12: Symptoms of STGD1 & Dry AMD
Symptoms of STGD1 & Dry AMD Symptoms of STGD1 Symptoms of Dry AMD Reference: https://makariwellness.com/stargardt-disease/ https://www.ncbi.ie/supporting-you/everyday-living/eye-conditions/age-related-macular-degeneration-amd/
Slide 13: RBP4 Reduction Reduces A2E Accumulation by 80%
Effect of LBS-008 on biomarkers in a STGD1 mouse model (ABCA4-/-/RDH8-/-) RBP4 Reduction Reduces A2E Accumulation by 80% • Daily dosing at approx. 25mg/kg of LBS-008 for 12 weeks (LBS-008-supplemented chow ad libitum). • A mean RBP4 reduction of ~90% in LBS-008 treated mice led to an ~80% reduction
Slide 14: RBP4 Reduction Preserves Photoreceptor Cells
Effect of LBS-008 on retinal pathology in a STGD1 mouse model (ABCA4-/-/RDH8-/-) RBP4 Reduction Preserves Photoreceptor Cells • Outer Nuclear Layer (ONL) thickness was significantly decreased in untreated ABCA4-/-/RDH8-/- mice, compared to mice treated with LBS- 008 • Macular degeneration in Dry AMD
Slide 15: LBS-007 for Broad Variety of Cancers
LBS-007 FOR BROAD VARIETY OF CANCERS 15
Slide 16: Natural non-ATP CDC7 Inhibitor for Broad Variety of Cancer Types
Natural non-ATP CDC7 Inhibitor for treatment of Broad Variety of Cancer types DISCOVERY ✓ PRE-CLINICAL PHASE I KEY OPPORTUNITY MARKET PHASE II/III MARKET Novel Anti-Cancer Target Therapy $5B 1.7 in 100k Expected 2026 market Acute lymphoblastic leukemia size of AML & ALL (orphan disease) ODD for ALL
Slide 17: Inhibits CDC7 in Cell Cycle Regulation
Inhibits CDC7 in Cell Cycle Regulation LBS-007 1 TARGETS 2 INHIBITS 3 PREVENTS S Phase Progression CDC7’s role in Cell Division DNA Replication 17
Slide 18: Potently Inhibits Multiple Cancer Cell Lines & Primary Patient Samples of Blood Cancers
Potently Inhibits Multiple Cancer Cell Lines & Primary Patient Samples of Blood Cancers EC50 (nanoM) 5 1000 Lymphoma Lung Cancer Breast Cancer Hematopoietic Primary Patient Solid Tumor Cell Line Sample Cell Line 18
Slide 19: LBS-007 Works Well on Small Cell Lung Cancer and Pancreatic Cell Lines
LBS-007 works well on small cell lung cancer and pancreatic cell lines P a n c -1 Pancreatic Cancer SmallHCell 146 - S C LC Lung Cancer ⚫ LBS-007 achieved sub-μM (~150 nM) concentration L B S -0 0 7 1B. 0M S 8 6 3 - 2 3 3 R e la tiv e V ia b ility 1 .0 R e la tiv e V ia b ility efficacy against canc
Slide 20: LBS-007 – Effective Against Blood Cancers
LBS-007 – Effective Against Blood Cancers Inhibits TKI-Resistant Acute Lymphoblastic Leukemia (ALL) growth in vivo using a continuous infusion regimen Reference: Unpublished data from Dr. Mark Frattini DORSAL VENTRAL DOSE-RESPONSIVE MANNER 20
Slide 21: LBS-007 – Also Effective Against Solid Tumors in Animal Models
LBS-007 – Also Effective Against Solid Tumors in Animal Models Inhibits Ovarian Tumor growth in vivo Color Bar Min = 1e+06 Max = 3e+08 Control 0.3 1 3 mg/kg Reference: Unpublished data from DOSE-RESPONSIVE MANNER Dr. Mark Frattini 21
Slide 22: Thank You
Thank You This presentation is provided by Lin Bioscience, Inc. (“LBS”). The information contained within is not reviewed or reviewed by any accountant or any independent third party. Users should read this material in conjunction with all other public financial and operational information filed to
Slide 23: Blindness & Cancer
Blindness & Cancer [email protected] 23